20 November 2025 | Thursday | News
Image Source : Public Domain
CRScube has announced the successful acquisition of Mednet, marking a key milestone in its global strategic growth and expansion into the North American market. The transaction unites two respected eClinical technology vendors with complementary strengths and a shared commitment to thoughtful innovation, collaboration, and care for the people behind every trial.
The companies bring deep expertise in Software as a Service (SaaS), trusted by sponsors and CROs in pharmaceuticals, biotechnology, and medical devices. CRScube is Korea's #1 eClinical provider, having supported 6,000+ trials worldwide and recognized on G2.com for the highest user satisfaction among EDC vendors. Mednet was born and bred in the US and has supported over 100 FDA approvals through their EDC-centric eClinical platform.
Beyond electronic data capture (EDC), CRScube and Mednet's combined suite of integrated eClinical solutions includes randomization and trial supply management (RTSM), electronic patient-reported outcome (ePRO), Clinical Trial Management System (CTMS), Electronic Trial Master File (eTMF) and more. Their portfolio offers a more complete, scalable set of solutions to design, build, and manage all types of clinical trials more efficiently – directly addressing the growing demand for flexible and connected technologies in a rapidly evolving life sciences industry.
By combining CRScube's leadership in Asia with Mednet's market experience, client relationships, and operational excellence in North America, the merged organization will deliver a unified approach to eClinical technology, strengthened by local expertise and insight.
"Bringing CRScube and Mednet together is an important milestone in our journey to transform clinical trials," said Stanley Kim, CEO of CRScube. "We believe research should be simpler, smarter, and more human – and this acquisition is about turning that belief into reality on a global scale. We're excited to deliver not only innovative technology, but also the trust, care, and responsiveness that clinical teams and patients deserve."
Rob Robertson, CEO of Mednet, added: "This is an exciting time for both organizations. For more than 20 years, Mednet has worked side by side with sponsors and CROs to help them succeed. Joining CRScube allows us to build on that foundation and scale our impact even further – creating new opportunities for our clients, our employees, and, most importantly, the patients whose lives depend on research."
In the months ahead, CRScube and Mednet will work closely to align operations and explore new opportunities for integration. While each company will continue serving its existing clients without disruption, this transaction lays the foundation for a future where scale and service, speed and quality, and innovation and accessibility are delivered together, without compromise.
Most Read
Bio Jobs
News
Editor Picks